STAAR Surgical Company (STAA)

STAAR Surgical's stock experienced several significant events in the past six months. Preliminary first-quarter 2026 net sales exceeded $90 million, leading to a stock surge and an upgrade from Canaccord Genuity. Prior to this, the company reported disappointing fourth-quarter and full-year 2025 results, with net sales declining by 23.7% year-over-year. A definitive merger agreement with Alcon was terminated. As of April 7, 2026, the share price was $21.09, representing a 39.76% increase over the price of $15.09 on April 8, 2025.

Demand for STAAR Surgical's products exhibits seasonality, with the second quarter typically being the strongest. In the United States, summer seasonality can lead to lower sales, followed by a reacceleration in the fourth quarter. In China, the summer high season is anticipated to lead to increased demand. However, demand in China has been volatile, with a significant decline in ICL sales in the fourth quarter of 2024 due to macroeconomic conditions and weak consumer consumption. In-market demand in China accelerated in the fourth quarter of 2025, providing a positive signal for fiscal 2026.

STAAR Surgical Co. is a global ophthalmic surgery company specializing in implantable lenses for vision correction, primarily Implantable Collamer Lenses (ICLs) like the EVO family, which correct visual disorders as an alternative to glasses, contacts, and laser surgery. The company generates almost all of its revenue from ICL sales and has phased out IOLs for cataract surgery.

STAAR Surgical has a global presence, selling in over 75 countries, with direct distribution in key markets like Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore. In other regions, it uses a combination of direct distribution and independent distributors. The company's administrative offices and principal manufacturing are in Lake Forest, California, with additional facilities in California and Switzerland. Operations in Japan drive market adoption, and its presence in South Korea has been boosted by the first ICL-only clinic.

STAAR Surgical is regarded as a technology leader in the ophthalmic industry, with its brand reputation influenced by both challenges and successes. Positive indicators include preliminary Q1 2026 sales exceeding expectations, surpassing 4 million ICLs sold globally, and the EVO ICL holding a dominant market share in the U.S. high-myopia segment and China's phakic intraocular lens market. Reputational challenges arose from fluctuating demand in China, leading to sales declines and increased inventory, as well as the uncertainty caused by the terminated merger agreement with Alcon. Despite these challenges, the company's commitment to innovation and patient outcomes underpins its long-term brand strength.

Institutional investors hold a dominant role in STAAR Surgical's ownership, with 210 institutional owners and shareholders holding a total of 52,616,729 shares as of April 10, 2026. Major institutional shareholders include Broadwood Capital Inc., BlackRock, Inc., Vanguard Group Inc., Yunqi Capital Ltd., Magnetar Financial LLC, Goldman Sachs Group Inc., State Street Corp, Balyasny Asset Management Llc, Geode Capital Management, Llc, and Morgan Stanley. Broadwood Partners LP is a significant individual shareholder, owning 36.01 million shares, representing 72.73% of the company. Neal C. Bradsher may be deemed to beneficially own 16,149,742 shares, or 32.6% of the outstanding stock, through personal holdings and Broadwood Partners.